10-QPeriod: Q2 FY2012

AGILENT TECHNOLOGIES, INC. Quarterly Report for Q2 Ended Apr 30, 2012

Filed June 4, 2012For Securities:A

Summary

Agilent Technologies reported solid financial results for the quarter ended April 30, 2012, with total net revenue increasing by 3% to $1.733 billion and net income rising to $255 million, up from $200 million in the prior year period. This growth was driven by strong performance across its key segments, particularly in Chemical Analysis and Electronic Measurement, despite a slight dip in Life Sciences orders. The company also announced a significant strategic move with the proposed acquisition of Dako A/S for approximately $2.2 billion, to be funded by existing cash reserves, signaling a commitment to expanding its diagnostics and pathology offerings. Operationally, Agilent demonstrated disciplined expense management, with selling, general, and administrative expenses decreasing year-over-year. The company generated $503 million in cash from operating activities for the six-month period, underscoring its strong cash-generation capabilities. Agilent also initiated a quarterly cash dividend, returning capital to shareholders. Looking ahead, the company expressed confidence in navigating economic uncertainties and leveraging growth opportunities, particularly in emerging markets.

Financial Highlights

58 data points
Beta

Revenue

$1.73B

53.0% Gross Margin

Net Income

$255.00M

14.7% Net Margin

EPS (Diluted)

$0.72

Total Assets

$9.41B

Cash & Equivalents

$3.90B

Free Cash Flow

$316.00M

Financial Statements
Beta
Revenue$1.73B
Cost of Revenue$815.00M
Gross Profit$918.00M
R&D Expenses$166.00M
SG&A Expenses$452.00M
Operating Expenses$1.43B
Operating Income$300.00M
Interest Expense$25.00M
Net Income$255.00M
EPS (Basic)$0.73
EPS (Diluted)$0.72
Shares Outstanding (Basic)348.00M
Shares Outstanding (Diluted)354.00M

Key Highlights

  • 1Total net revenue for the three months ended April 30, 2012, increased 3% year-over-year to $1.733 billion.
  • 2Net income for the three months ended April 30, 2012, rose to $255 million ($0.72 per diluted share) from $200 million ($0.56 per diluted share) in the prior year period.
  • 3Announced the proposed acquisition of Dako A/S for approximately $2.2 billion, to be funded by existing cash, indicating a strategic expansion into diagnostics.
  • 4Generated $503 million in cash from operating activities for the six months ended April 30, 2012, reflecting strong operational cash flow.
  • 5Initiated a quarterly cash dividend of $0.10 per share, signaling a commitment to returning capital to shareholders.
  • 6Electronic Measurement orders saw a significant 13% increase, driven by strong wireless manufacturing and industrial demand.
  • 7Maintained a healthy cash and cash equivalents balance of $3.9 billion as of April 30, 2012.

Frequently Asked Questions

For the quarter ended April 30, 2012, Agilent Technologies reported total net revenue of $1.733 billion, a 3% increase compared to the same period last year. Net income was $255 million, or $0.72 per diluted share, an increase from $200 million, or $0.56 per diluted share, in the prior year. The company also saw a 13% increase in orders for its Electronic Measurement segment.

The most significant strategic announcement is the proposed acquisition of Dako A/S for approximately $2.2 billion, which Agilent plans to fund using its existing cash reserves. This acquisition is expected to enhance Agilent's offerings in the diagnostics and pathology markets. Additionally, the company initiated a quarterly cash dividend of $0.10 per share.

Agilent maintained a strong liquidity position with $3.9 billion in cash and cash equivalents as of April 30, 2012. The company generated $503 million in cash from operations for the first six months of the fiscal year and has access to a $400 million unsecured credit facility. They plan to use existing cash for the Dako acquisition and are confident in their ability to meet future liquidity needs.

Agilent's performance varied by segment. Life Sciences orders saw a slight decline, while Chemical Analysis orders grew 7% and Electronic Measurement orders significantly increased by 13% for the quarter. Revenue growth was positive across all segments, with Life Sciences and Chemical Analysis showing strong performance, particularly in pharmaceutical, biotechnology, and various industrial applications.